SV2003001494A - Derivados de aminoindazoles, procedimiento de su preparacion e intermedios de dicho procedimiento titulo de medicamentos y composiciones farmaceuticas que los contienen - Google Patents

Derivados de aminoindazoles, procedimiento de su preparacion e intermedios de dicho procedimiento titulo de medicamentos y composiciones farmaceuticas que los contienen

Info

Publication number
SV2003001494A
SV2003001494A SV2003001494A SV2003001494A SV2003001494A SV 2003001494 A SV2003001494 A SV 2003001494A SV 2003001494 A SV2003001494 A SV 2003001494A SV 2003001494 A SV2003001494 A SV 2003001494A SV 2003001494 A SV2003001494 A SV 2003001494A
Authority
SV
El Salvador
Prior art keywords
procedure
derivatives
aminoindazols
medicines
intermediates
Prior art date
Application number
SV2003001494A
Other languages
English (en)
Inventor
Gilles Dutruc-Rosset
Dominique Lessuisse
Thomas Rooney
Franck Halley
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of SV2003001494A publication Critical patent/SV2003001494A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a los nuevos derivados de indazol de fórmula general (I) en la que: R es bien O, S o NH; R3 es un radical alquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, arilo, heterociclo, cicloalquilo, alquenilo...; estando etos radicales eventualmente substituidos por 1 o varios substituyentes; R4, R5, R6 y R7 se eligen, independientemente entre si, entre los radicales suguientes: hidrógeno, halóheno, CN, NO2, OH, COOH, C(O)OR8, -O-C(O)R8R9, NHC(O)R8, C(O)NR8R9, NHC(S)R8, C(S)NR8R9, SR8, S(O)R8, SO2R8, NHSO2R8, SO2NR8R9, triflúormetilo, triflúormetoxi, alquilo, alcoxi, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclo, cicloalquilo, alquenilo...; estando substituidos los radicales, eventualmente por 1 o varios sustituyentes
SV2003001494A 2002-03-11 2003-03-03 Derivados de aminoindazoles, procedimiento de su preparacion e intermedios de dicho procedimiento titulo de medicamentos y composiciones farmaceuticas que los contienen SV2003001494A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0202997A FR2836915B1 (fr) 2002-03-11 2002-03-11 Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant

Publications (1)

Publication Number Publication Date
SV2003001494A true SV2003001494A (es) 2003-07-10

Family

ID=27763685

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2003001494A SV2003001494A (es) 2002-03-11 2003-03-03 Derivados de aminoindazoles, procedimiento de su preparacion e intermedios de dicho procedimiento titulo de medicamentos y composiciones farmaceuticas que los contienen

Country Status (30)

Country Link
US (1) US6949579B2 (es)
EP (1) EP1487804B1 (es)
JP (2) JP4648630B2 (es)
KR (1) KR101068770B1 (es)
CN (2) CN101962365A (es)
AR (1) AR038915A1 (es)
AU (1) AU2003242809B8 (es)
BR (1) BR0308373A (es)
CA (1) CA2478542C (es)
FR (1) FR2836915B1 (es)
GT (1) GT200300057A (es)
HR (1) HRP20040824B1 (es)
IL (2) IL163831A0 (es)
JO (1) JO2326B1 (es)
MA (1) MA27230A1 (es)
ME (2) ME00058B (es)
MX (1) MXPA04007478A (es)
MY (1) MY138269A (es)
NO (1) NO329384B1 (es)
NZ (1) NZ535147A (es)
PA (1) PA8568301A1 (es)
PE (1) PE20040155A1 (es)
PL (1) PL370478A1 (es)
RS (1) RS52396B (es)
RU (1) RU2345070C2 (es)
SV (1) SV2003001494A (es)
TW (1) TWI329103B (es)
UY (1) UY27713A1 (es)
WO (1) WO2003078403A2 (es)
ZA (1) ZA200406687B (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2836914B1 (fr) 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
CA2486101C (en) * 2002-05-17 2009-07-07 Pharmacia Italia S.P.A. Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
JP4648703B2 (ja) * 2002-09-05 2011-03-09 アベンティス・ファーマ・ソシエテ・アノニム 医薬としての新規なアミノインダゾール誘導体及びこれらを含む医薬組成物
JP4401298B2 (ja) 2002-12-02 2010-01-20 エフ．ホフマン−ラ ロシュ アーゲー Ｃｒｆアンタゴニストとしてのインダゾール誘導体
FR2848554A1 (fr) * 2002-12-12 2004-06-18 Aventis Pharma Sa Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
BR0316606A (pt) 2002-12-12 2005-10-11 Aventis Pharma Sa Derivados de aminoindazóis e sua utilização como inibidores de quinases
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP4734119B2 (ja) * 2004-02-12 2011-07-27 田辺三菱製薬株式会社 インダゾール化合物及びその医薬用途
FR2871158A1 (fr) * 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
MX2007000791A (es) 2004-08-03 2007-03-23 Wyeth Corp Indazoles utiles en el tratamiento de enfermedades cardiovasculares.
ATE478852T1 (de) * 2005-09-09 2010-09-15 Schering Corp Neue 4-cyano-, 4-amino-, und 4- aminomethylderivative von pyrazoloä1,5- aüpyridinen, pyrazoloä1,5-cüpyrimidinen und 2h- indazolverbindungen und 5-cyano-, 5-amino- und 5- aminomethylderivative von imidazoä1,2-aüpyridinen,und imidazoä1,5-aüpyrazinverbindungen als inhibitoren der cyclinabhänggen kinase
MY151835A (en) 2006-01-31 2014-07-14 Array Biopharma Inc Kinase inhibitors and methods of use thereof
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
EP2120932B1 (en) 2006-12-20 2014-07-09 Nerviano Medical Sciences S.r.l. Indazole derivatives as kinase inhibitors for the treatment of cancer
DE102007022565A1 (de) * 2007-05-14 2008-11-20 Merck Patent Gmbh Heterocyclische Indazolderivate
PL2176231T3 (pl) 2007-07-20 2017-04-28 Nerviano Medical Sciences S.R.L. Podstawione pochodne indazolu aktywne jako inhibitory kinazy
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5693239B2 (ja) 2008-01-23 2015-04-01 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ４−ピリジノン化合物および癌についてのその使用
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8354399B2 (en) * 2008-12-18 2013-01-15 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
KR101771193B1 (ko) 2009-04-30 2017-09-05 글락소 그룹 리미티드 Ｐｉ3­키나아제 억제제로서 옥사졸 치환된 인다졸
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CA2791613A1 (en) * 2010-03-16 2011-09-22 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2012340200B2 (en) 2011-11-17 2017-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-Terminal Kinase (JNK)
WO2013100566A1 (en) * 2011-12-27 2013-07-04 Bio-Pharm Solutions Co., Ltd. Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
ES2676734T3 (es) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
CN103739550B (zh) * 2014-01-02 2016-06-01 中国药科大学 2,3-二甲基-6-脲-2h-吲唑类化合物及其制备方法与应用
SG11201605917SA (en) * 2014-01-24 2016-08-30 Abbvie Inc 6-phenyl- or 6-(pyridin-3-yl)indazole derivatives and methods of use
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
KR101731624B1 (ko) * 2014-07-01 2017-05-04 광주과학기술원 세포 리프로그래밍 유도용 조성물
KR102022866B1 (ko) 2014-08-19 2019-09-19 상하이 하이헤 파마수티컬 컴퍼니 리미티드 섬유 아세포 성장 인자 수용체 키나아제 억제제인 인다졸계 화합물 및 이의 제조와 응용
AU2015355220B2 (en) 2014-12-02 2020-02-27 Ignyta, Inc. Combinations for the treatment of neuroblastoma
EP3233840B1 (en) 2014-12-16 2018-11-21 Eudendron S.r.l. Heterocyclic derivatives modulating activity of certain protein kinases
EP3236959A4 (en) 2014-12-23 2018-04-25 Dana Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CA2978518C (en) 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
CN106279119B (zh) * 2015-05-27 2020-06-16 上海海和药物研究开发有限公司 一种新型激酶抑制剂的制备及其应用
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
MX2018004879A (es) * 2015-10-22 2019-02-28 Selvita S A Nuevos derivados de piridona y su uso como inhibidores de quinasas.
CN105467027B (zh) * 2015-11-18 2021-09-21 北京万全德众医药生物技术有限公司 一种用气相色谱法分离测定米诺膦酸中间体有关物质的方法
WO2017106492A1 (en) 2015-12-18 2017-06-22 Ignyta, Inc. Combinations for the treatment of cancer
AU2018302170B2 (en) 2017-07-19 2024-02-29 Ignyta, Inc. Pharmaceutical compositions comprising entrectinib
CN111032646B (zh) 2017-08-01 2023-01-03 施万生物制药研发Ip有限责任公司 作为jak激酶抑制剂的吡唑并和三唑并双环化合物
EP3697390A1 (en) 2017-10-17 2020-08-26 Ignyta, Inc. Pharmaceutical compositions and dosage forms
CN110117278B (zh) * 2018-02-07 2022-07-19 石家庄以岭药业股份有限公司 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途
WO2020086505A1 (en) 2018-10-24 2020-04-30 Bristol-Myers Squibb Company Substituted indole dimer compounds
JP2022505707A (ja) * 2018-10-24 2022-01-14 ブリストル－マイヤーズ スクイブ カンパニー 置換インドールおよびインダゾール化合物
US10851102B2 (en) 2019-01-23 2020-12-01 Theravance Biopharma R&D Ip, Llc Imidazole and triazole containing bicyclic compounds as JAK inhibitors
WO2021110891A1 (en) * 2019-12-04 2021-06-10 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic amino compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133081A (en) * 1964-05-12 J-aminoindazole derivatives
US2971842A (en) * 1956-03-21 1961-02-14 Gen Aniline & Film Corp Light sensitive layers for photomechanical reproduction
DE1280878B (de) * 1961-11-30 1968-10-24 Smith Kline French Lab 3-Aminoindazole
GB965511A (en) * 1961-11-30 1964-07-29 Smith Kline French Lab Improvements in or relating to 3-aminoindazole derivatives
BE626284A (es) * 1962-04-28
US3720671A (en) * 1970-10-05 1973-03-13 Ciba Geigy Ag Polycyclic dyestuffs
FR2111641A2 (en) * 1970-10-09 1972-06-09 Geigy Ag J R Polycyclic cpds as dispersion dyestuffs for - hydrophobic organic fibres
DE2458965C3 (de) * 1974-12-13 1979-10-11 Bayer Ag, 5090 Leverkusen 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel
JPS51143010A (en) * 1975-06-04 1976-12-09 Kao Corp Stable bleaching detergent composition
SU742430A1 (ru) * 1978-11-09 1980-06-25 Предприятие П/Я А-7850 Способ получени 3-амино-5-нитроиндазола
DE3381617D1 (de) * 1982-03-17 1990-07-05 Asahi Chemical Ind Indazol-derivate.
JPS58159473A (ja) * 1982-03-17 1983-09-21 Asahi Chem Ind Co Ltd ベンゼン環置換基を有する新規な１位置換インダゾ−ル誘導体およびその製造法
KR940021073A (ko) * 1993-03-02 1994-10-17 미야베 요시가즈 알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i
KR100423899B1 (ko) * 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸

Also Published As

Publication number Publication date
JP4648630B2 (ja) 2011-03-09
ZA200406687B (en) 2005-10-26
UY27713A1 (es) 2003-09-30
MY138269A (en) 2009-05-29
BR0308373A (pt) 2005-01-11
JP2005530711A (ja) 2005-10-13
NZ535147A (en) 2007-08-31
MA27230A1 (fr) 2005-02-01
JP2010222357A (ja) 2010-10-07
FR2836915A1 (fr) 2003-09-12
CN1656078A (zh) 2005-08-17
CA2478542A1 (fr) 2003-09-25
RS52396B (en) 2013-02-28
RS79504A (en) 2006-12-15
HRP20040824B1 (hr) 2013-05-31
CA2478542C (fr) 2012-02-21
EP1487804B1 (fr) 2014-02-26
AU2003242809B2 (en) 2010-03-18
KR101068770B1 (ko) 2011-09-30
US6949579B2 (en) 2005-09-27
GT200300057A (es) 2006-10-19
MEP16108A (en) 2010-06-10
JO2326B1 (en) 2006-06-28
HRP20040824A2 (en) 2005-06-30
PE20040155A1 (es) 2004-04-18
RU2004129780A (ru) 2005-04-10
NO20044137L (no) 2004-11-25
ME00058B (me) 2010-10-10
WO2003078403A3 (fr) 2004-04-22
KR20040091121A (ko) 2004-10-27
WO2003078403A2 (fr) 2003-09-25
FR2836915B1 (fr) 2008-01-11
IL163831A (en) 2010-12-30
NO329384B1 (no) 2010-10-11
AU2003242809A1 (en) 2003-09-29
MXPA04007478A (es) 2004-11-10
TW200403226A (en) 2004-03-01
IL163831A0 (en) 2005-12-18
RU2345070C2 (ru) 2009-01-27
EP1487804A2 (fr) 2004-12-22
TWI329103B (en) 2010-08-21
AU2003242809B8 (en) 2010-04-15
CN101962365A (zh) 2011-02-02
JP5315287B2 (ja) 2013-10-16
PL370478A1 (en) 2005-05-30
US20040014802A1 (en) 2004-01-22
PA8568301A1 (es) 2005-02-04
AR038915A1 (es) 2005-02-02

Similar Documents

Publication Publication Date Title
SV2003001494A (es) Derivados de aminoindazoles, procedimiento de su preparacion e intermedios de dicho procedimiento titulo de medicamentos y composiciones farmaceuticas que los contienen
HUP0301113A2 (hu) Pirrolidinszármazékok, mint ciklusos amp-specifikus foszfodiészteráz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0000079A2 (hu) Indán- és dihidroindolszármazékok
AR040031A1 (es) Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen
HUP0400561A2 (hu) 3-Aroilindol-származékok és a vegyületek CB2 receptor agonistaként való alkalmazása, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0302485A2 (hu) Arilmetilamin-származékok triptáz gátlóként való alkalmazásra és ezeket tartalmazó gyógyszerkészítmények
CO6190582A2 (es) Derivados de heteroarilamida
HUP0402310A2 (hu) 1,6-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények
DE60335869D1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
NO20050741L (no) Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den
CO4950625A1 (es) Derivados de nicotinamida
NO980442D0 (no) <omega>-cykloalkyl-prostagladin-E2 -derivater
HUP0104218A2 (hu) Új szubsztituált fenil-ciklohexil vegyületekből származó észterek
RU2007143512A (ru) ИМИДАЗО[1,2-a]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ, КОТОРЫЕ МОЖНО ИСПОЛЬЗОВАТЬ В КАЧЕСТВЕ ИНГИБИТОРОВ ПЕПТИДДЕФОРМИЛАЗЫ
EA200300982A1 (ru) Гетероциклические производные для лечения рака и других пролиферативных заболеваний
MA27795A1 (fr) Derives d'amine cycliques, procedes de preparation de ceux-ci et compositions pharmaceutiques les contenant
ATE482933T1 (de) Sulfopyrrolderivate
ATE548042T1 (de) Prostansäurederivate zur senkung des augeninnendrucks
ATE525366T1 (de) Benzoxazolderivate und pharmazeutische zubereitungen die diese enthalten
AR011964A1 (es) Un compuesto derivado de (1h-indol-2-il)-5-[(2h-pirrol-2-ilideno)metil]-1h- pirrol, su utilizacion, un procedimiento para producirlo, productos ycomposiciones farmaceuticas que comprenden a dicho compuesto, un compuesto util como intermediario para preparar a dicho compuesto y una preparacion de
HUP0103020A2 (hu) Heterociklusos származékok mint FKBP inhibitorok, eljárás az előállításukra, köztitermékeik és ezeket tartalmazó gyógyszerkészítmények
MY138085A (en) Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them
RU2007148439A (ru) Активатор для рецептора, активируемого пролифератором пероксисом
RS20050165A (en) Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same
NO20061152L (no) Ny fremgangsmate for syntese av N-(S)-1-karboksybuty)-(S)-alanin og anvendelse derav for a syntetisere perindopril

Legal Events

Date Code Title Description
FD Lapse